title: [Percutaneous ethanol injection therapy for small hepatocellular carcinoma].
abstract: Hepatocellular carcinoma is different from other solid tumors. Because of concomitant cirrhosis or multiple lesions, most hepatocellular carcinoma is unresectable. Still worse, hepatocellular carcinoma frequently recurs after surgical resection; the 5-year cumulative recurrence rate is 70-90% even after curative hepatectomy. The situation is similar in small hepatocellular carcinoma 2 cm or less in diameter. Thus, non-surgical treatment plays an important role. At present, we think that percutaneous ethanol injection therapy (PEIT) is best for the treatment of hepatocellular carcinoma because of its local curativity, minimal adverse effect on liver function, and the easy feasibility of repeated treatment for recurrence. We have recently treated about 85% of hepatocellular carcinoma cases by PEIT and have achieved satisfactory long-term results. Here we describe our results in PEIT for small hepatocellular carcinoma. By the end of December 1995, we performed PEIT on 410 patients with hepatocellular carcinoma. Among them, 140 patients were diagnosed as having small hepatocellular carcinoma 2 cm or less in diameter. The 1-, 3-, 5-, 7-, and 10-year survival rates of the 140 patients were 93%, 73%, 55%, 51%, and 32%, respectively. Furthermore, in 83 patients who had a single, small hepatocellular carcinoma 2 cm or less in diameter, the 1-, 3-, 5-, 7-, and 10-year survival rates were 92%, 82%, 72%, 66%, and 66%, respectively. Thus PEIT achieved satisfactory long-term survival rates in the treatment of small hepatocellular carcinoma.
authors.affiliation: Dept. of Internal Medicine II, University of Tokyo, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Shiina
authors.forename: M
authors.initials: M
authors.lastname: Imamura
authors.forename: S
authors.initials: S
authors.lastname: Obi
authors.forename: T
authors.initials: T
authors.lastname: Teratani
authors.forename: F
authors.initials: F
authors.lastname: Kanai
authors.forename: N
authors.initials: N
authors.lastname: Kato
authors.forename: Y
authors.initials: Y
authors.lastname: Niwa
authors.forename: T
authors.initials: T
authors.lastname: Okudaira
authors.forename: D A
authors.initials: DA
authors.lastname: Payawal
authors.forename: R
authors.initials: R
authors.lastname: Tateishi
authors.forename: Y
authors.initials: Y
authors.lastname: Shiratori
authors.forename: M
authors.initials: M
authors.lastname: Omata
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000431:Ethanol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D017741:Survivors
chemical_list: D000431:Ethanol